3 treatment goals met
The PRISMS study
The 2-year PRISMS* study included 560 people to see how they responded to Rebif® (interferon beta-1a) 22 mcg or Rebif 44 mcg versus placebo, all given under the skin 3 times a week. The results revealed that Rebif 44 mcg:
- Showed a 78% reduction in the median number of T2 active lesions per patient per scan as compared to placebo (0.5 vs. 2.25 lesions)†.
- Nearly doubled the time to relapse. 4.5, 7.6 and 9.6 months for placebo, 22 mcg, and 44 mcg respectively.
- Rebif 44 mcg was proven to nearly double the time to disability progression.
The exact correlation between MRI findings and the current or future clinical status of patients, including disability progression, is unknown.
The PRISMS study demonstrated that people taking Rebif experienced a reduction in the development of new brain lesions on MRI†, reduced relapses and slowed progression of disability as compared to placebo
The 2-year PRISMS study also showed only 26% of people taking Rebif 44 mcg had disability progression‡—as opposed to 37% of those taking a placebo. The time to progression of disability, which is the permanent worsening of your neurologic examination over time, was also nearly doubled versus placebo (21.3 months vs 11.9 months).
In the PRISMS study, 3% of those taking Rebif 22 mcg and 5% taking Rebif 44 mcg stopped taking Rebif because of adverse events
It's important to inform your health care provider of any side effects you experience. There may be things you can do to help manage them.
*Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis.
†New or enlarging lesions detected with PD/T2-weighted MRI.
‡Progression of disability was defined as an increase of at least 1 point in the EDSS that was sustained for at least 3 months.